BridgeBio to present new acoramidis kidney function data at amyloidosis symposium
BBIO•BBIO•BBIO•BBIO•BridgeBio will present 28 acoramidis abstracts at the International Symposium on Amyloidosis in Montevideo, Uruguay, from November 15-18, 2026. New analyses examine kidney-function changes and real-world treatment findings in transthyretin amyloid cardiomyopathy.
BridgeBio will present 28 acoramidis abstracts at the International Symposium on Amyloidosis. New analyses examine kidney function in transthyretin amyloid cardiomyopathy; one found early kidney-function changes without clinically meaningful laboratory or blood-pressure changes. Real-world findings show lower initiation of transthyretin silencer therapy with acoramidis than with tafamidis, while another analysis indicates earlier reductions in heart-failure events. Licensing partner Bayer will present German real-world data comparing the treatments on diuretic intensification, a marker of worsening heart failure.
